A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
Study with mint Lesion™ compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis
A study conducted by researchers at University Hospital Tuebingen retrospectively compared two liver-targeted therapies for uveal melanoma patients…
ESOI-EORTC Workshop on Imaging in Assessing Response to Cancer Therapy - A Participant's Perspective
Following the conclusion of the ESOI-EORTC Workshop on Imaging in Assessing Response to Cancer Therapy in Munich, we were keen to gather feedback…
University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy
A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…